Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Japan Biz of Top 3 Generic Makers in H1 Impacted by GMP Issues, Substitution Demand: Jiho Tally
November 25, 2021
-
BUSINESS Alnylam to File Its Third Drug in Japan 3 Years after Market Entry, Eyes CNS Therapies
November 24, 2021
-
ORGANIZATION 20% of Listed Drugs in Japan, Mostly Generics, Hit by Supply Issues: FPMAJ Survey
November 22, 2021
-
REGULATORY Japan OKs 56 Trillion Yen Stimulus Package, Spells Out Support for Japan-Made Drugs and Vaccines
November 22, 2021
-
BUSINESS Top 4 Wholesalers’ Average Operating Margin at 0.46% on Tough Price Negotiations: H1 FY2021 Earnings
November 22, 2021
-
REGULATORY Japan Panel Discusses Safety, Immunity Rules for Envisaged Emergency Approval Scheme
November 19, 2021
-
REGULATORY Ex-Minister Tamura Says Efficacy/Safety Confirmation Important in Emergency Approval, Wary on Macroeconomic Indexing
November 18, 2021
-
BUSINESS Otsuka’s Eczema Drug, 2 More Products Skip November Listing
November 18, 2021
-
BUSINESS Aducanumab Gets “Negative Trend Vote” in Europe: Biogen/Eisai
November 18, 2021
-
REGULATORY 50 Billion Yen-Plus Peak Sales Projected for Pfizer’s Vynmac, Listing Set for Nov. 25
November 17, 2021
-
COMMENTARY MOF, MHLW Push Conflicting Narratives on Drug Cost Control; Macroeconomic Indexing Is a Major Focus Too
November 16, 2021
-
REGULATORY Japan to Use mRNA Jabs for Boosters, Pfizer Vaccine for Time Being: Panel
November 16, 2021
-
BUSINESS Ono to Pay 28 Billion Yen to Settle Opdivo Feud with Honjo
November 15, 2021
-
REGULATORY Govt to Provide Up to 2 Billion Yen per Oral COVID-19 Drug to Support Development
November 15, 2021
-
BUSINESS Aikomi, Sumitomo Dainippon Eye Therapeutic App Approval for BPSD by 2027
November 12, 2021
-
ORGANIZATION Ex-MHLW Bureau Chief Calls for 6% Adjustment Rate, Frowns on Macroeconomic Indexing; Study Group Launch Next Month
November 11, 2021
-
REGULATORY Japan Approves Pfizer COVID-19 Vaccine for Booster Use
November 11, 2021
-
REGULATORY Japan to Receive 1.6 Million Courses of MSD’s COVID-19 Drug
November 11, 2021
-
BUSINESS Pfizer’s COVID-19 Vaccine Filed for Children 5 to 11 in Japan
November 10, 2021
-
BUSINESS 6 Wholesalers Raided over Suspected Bid-Rigging in Kyushu
November 10, 2021
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…